Skip to main content
Clinical Trials/JPRN-UMIN000047390
JPRN-UMIN000047390
Not yet recruiting
未知

Multicenter prospective study of Diverticulitis of the colon - Multicenter prospective study of Diverticulitis of the colon

Kawasaki Medical School0 sites300 target enrollmentApril 5, 2022

Overview

Phase
未知
Intervention
Not specified
Conditions
colonic diverticulitis
Sponsor
Kawasaki Medical School
Enrollment
300
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 5, 2022
End Date
July 31, 2023
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Patients denied colonic diverticulitis by imaging examinations

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
A Randomized, Double-Blind, Multicenter Study of Denosumab Compared with Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Men with Hormone-Refractory Prostate Cancer.
EUCTR2006-000341-19-GRAmgen Inc1,700
Active, not recruiting
Not Applicable
Double-blind Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Metastases in Men With Hormone-refractory Prostate Cancer
EUCTR2006-000341-19-SEAmgen Inc1,904
Active, not recruiting
Phase 1
A Randomized, Double-Blind, Multicenter Study of Denosumab ComparedWith Zoledronic Acid (Zometa) in the Treatment of Bone Disease inSubjects with Newly Diagnosed Multiple Myeloma
EUCTR2010-020454-34-ITAMGEN INC.1,718
Completed
Phase 3
A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Subjects with Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple MyelomaBone Metastases in Subjects with Advanced Cancer (Excluding Breast and Prostate Cancer) and Multiple Myeloma. Cancer (Except Breast and Prostate Cancer) spread to bone and Kahler's disease.1000595910027656
NL-OMON30155Amgen Inc.18
Active, not recruiting
Phase 1
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple MyelomaMultiple MyelomaMedDRA version: 20.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2010-020454-34-GBAmgen Inc1,700